FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2154894292> ?p ?o ?g. }

• W2154894292 endingPage "2279" @default.
• W2154894292 startingPage "2273" @default.
• W2154894292 abstract "On March 30, a novel influenza A subtype H7N9 virus (A/H7N9) was detected in patients with severe respiratory disease in eastern China. Virological factors associated with a poor clinical outcome for this virus remain unclear. We quantified the viral load and analysed antiviral resistance mutations in specimens from patients with A/H7N9.We studied 14 patients with A/H7N9 disease admitted to the Shanghai Public Health Clinical Centre (SPHCC), China, between April 4, and April 20, 2013, who were given antiviral treatment (oseltamivir or peramivir) for less than 2 days before admission. We investigated the viral load in throat, stool, serum, and urine specimens obtained sequentially from these patients. We also sequenced viral RNA from these specimens to study the mutations associated with resistance to neuraminidase inhibitors and their association with disease outcome.All patients developed pneumonia, seven of them required mechanical ventilation, and three of them further deteriorated to become dependent on extracorporeal membrane oxygenation (ECMO), two of whom died. Antiviral treatment was associated with a reduction of viral load in throat swab specimens in 11 surviving patients. Three patients with persistently high viral load in the throat in spite of antiviral therapy became ECMO dependent. An Arg292Lys mutation in the virus neuraminidase (NA) gene known to confer resistance to both zanamivir and oseltamivir was identified in two of these patients, both also received corticosteroid treatment. In one of them, wild-type sequence Arg292 was noted 2 days after start of antiviral treatment, and the resistant mutant Lys292 dominated 9 days after start of treatment.Reduction of viral load following antiviral treatment correlated with improved outcome. Emergence of NA Arg292Lys mutation in two patients who also received corticosteroid treatment led to treatment failure and a poor clinical outcome. The emergence of antiviral resistance in A/H7N9 viruses, especially in patients receiving corticosteroid therapy, is concerning, needs to be closely monitored, and considered in pandemic preparedness planning.National Megaprojects of China for Infectious Diseases, Shanghai Municipal Health and Family Planning Commission, the National Key Basic Research Program of China, Ministry of Science and Technology, and National Natural Science Foundation of China." @default.
• W2154894292 created "2016-06-24" @default.
• W2154894292 creator A5006065098 @default.
• W2154894292 creator A5008280608 @default.
• W2154894292 creator A5008659449 @default.
• W2154894292 creator A5009172372 @default.
• W2154894292 creator A5021175072 @default.
• W2154894292 creator A5024403120 @default.
• W2154894292 creator A5025943145 @default.
• W2154894292 creator A5027937292 @default.
• W2154894292 creator A5028519714 @default.
• W2154894292 creator A5030659566 @default.
• W2154894292 creator A5032930399 @default.
• W2154894292 creator A5038064048 @default.
• W2154894292 creator A5038296886 @default.
• W2154894292 creator A5041664384 @default.
• W2154894292 creator A5042519138 @default.
• W2154894292 creator A5042956973 @default.
• W2154894292 creator A5046380471 @default.
• W2154894292 creator A5046597133 @default.
• W2154894292 creator A5047547850 @default.
• W2154894292 creator A5051766799 @default.
• W2154894292 creator A5054578837 @default.
• W2154894292 creator A5070368039 @default.
• W2154894292 creator A5073008031 @default.
• W2154894292 creator A5076555816 @default.
• W2154894292 creator A5077484550 @default.
• W2154894292 creator A5079977131 @default.
• W2154894292 creator A5081338464 @default.
• W2154894292 creator A5084581495 @default.
• W2154894292 creator A5086326013 @default.
• W2154894292 creator A5090384031 @default.
• W2154894292 date "2013-06-01" @default.
• W2154894292 modified "2023-10-18" @default.
• W2154894292 title "Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance" @default.
• W2154894292 cites W1603867145 @default.
• W2154894292 cites W1996311210 @default.
• W2154894292 cites W2015237266 @default.
• W2154894292 cites W2039981276 @default.
• W2154894292 cites W2063205025 @default.
• W2154894292 cites W2104814883 @default.
• W2154894292 cites W2105226322 @default.
• W2154894292 cites W2106173155 @default.
• W2154894292 cites W2111005290 @default.
• W2154894292 cites W2133197143 @default.
• W2154894292 cites W2156658075 @default.
• W2154894292 cites W2318346408 @default.
• W2154894292 cites W4237236497 @default.
• W2154894292 cites W4296590891 @default.
• W2154894292 doi "https://doi.org/10.1016/s0140-6736(13)61125-3" @default.
• W2154894292 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23726392" @default.
• W2154894292 hasPublicationYear "2013" @default.
• W2154894292 type Work @default.
• W2154894292 sameAs 2154894292 @default.
• W2154894292 citedByCount "308" @default.
• W2154894292 countsByYear W21548942922013 @default.
• W2154894292 countsByYear W21548942922014 @default.
• W2154894292 countsByYear W21548942922015 @default.
• W2154894292 countsByYear W21548942922016 @default.
• W2154894292 countsByYear W21548942922017 @default.
• W2154894292 countsByYear W21548942922018 @default.
• W2154894292 countsByYear W21548942922019 @default.
• W2154894292 countsByYear W21548942922020 @default.
• W2154894292 countsByYear W21548942922021 @default.
• W2154894292 countsByYear W21548942922022 @default.
• W2154894292 countsByYear W21548942922023 @default.
• W2154894292 crossrefType "journal-article" @default.
• W2154894292 hasAuthorship W2154894292A5006065098 @default.
• W2154894292 hasAuthorship W2154894292A5008280608 @default.
• W2154894292 hasAuthorship W2154894292A5008659449 @default.
• W2154894292 hasAuthorship W2154894292A5009172372 @default.
• W2154894292 hasAuthorship W2154894292A5021175072 @default.
• W2154894292 hasAuthorship W2154894292A5024403120 @default.
• W2154894292 hasAuthorship W2154894292A5025943145 @default.
• W2154894292 hasAuthorship W2154894292A5027937292 @default.
• W2154894292 hasAuthorship W2154894292A5028519714 @default.
• W2154894292 hasAuthorship W2154894292A5030659566 @default.
• W2154894292 hasAuthorship W2154894292A5032930399 @default.
• W2154894292 hasAuthorship W2154894292A5038064048 @default.
• W2154894292 hasAuthorship W2154894292A5038296886 @default.
• W2154894292 hasAuthorship W2154894292A5041664384 @default.
• W2154894292 hasAuthorship W2154894292A5042519138 @default.
• W2154894292 hasAuthorship W2154894292A5042956973 @default.
• W2154894292 hasAuthorship W2154894292A5046380471 @default.
• W2154894292 hasAuthorship W2154894292A5046597133 @default.
• W2154894292 hasAuthorship W2154894292A5047547850 @default.
• W2154894292 hasAuthorship W2154894292A5051766799 @default.
• W2154894292 hasAuthorship W2154894292A5054578837 @default.
• W2154894292 hasAuthorship W2154894292A5070368039 @default.
• W2154894292 hasAuthorship W2154894292A5073008031 @default.
• W2154894292 hasAuthorship W2154894292A5076555816 @default.
• W2154894292 hasAuthorship W2154894292A5077484550 @default.
• W2154894292 hasAuthorship W2154894292A5079977131 @default.
• W2154894292 hasAuthorship W2154894292A5081338464 @default.
• W2154894292 hasAuthorship W2154894292A5084581495 @default.
• W2154894292 hasAuthorship W2154894292A5086326013 @default.
• W2154894292 hasAuthorship W2154894292A5090384031 @default.
• W2154894292 hasConcept C126322002 @default.

• next